Pulmonx Co. (NASDAQ:LUNG) Receives $14.83 Consensus Target Price from Brokerages

Shares of Pulmonx Co. (NASDAQ:LUNG) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $14.67.

A number of equities analysts have weighed in on the stock. Wells Fargo & Company decreased their target price on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Canaccord Genuity Group lifted their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Stifel Nicolaus cut their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday.

Pulmonx Trading Down 8.0 %

LUNG opened at $6.25 on Tuesday. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The stock has a market cap of $244.71 million, a PE ratio of -4.17 and a beta of 0.64. The business has a 50 day moving average of $7.27 and a 200-day moving average of $7.26.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The firm had revenue of $20.78 million for the quarter, compared to analysts’ expectations of $20.23 million. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. Equities research analysts predict that Pulmonx will post -1.64 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Geoffrey Beran Rose sold 4,586 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the sale, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, General Counsel David Aaron Lehman sold 5,765 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total value of $38,567.85. Following the transaction, the general counsel now owns 203,348 shares in the company, valued at $1,360,398.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Geoffrey Beran Rose sold 4,586 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total transaction of $30,726.20. Following the completion of the transaction, the insider now directly owns 295,433 shares in the company, valued at approximately $1,979,401.10. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,351 shares of company stock valued at $361,494 over the last three months. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Pulmonx by 4.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock worth $332,000 after purchasing an additional 1,633 shares in the last quarter. Sei Investments Co. increased its position in Pulmonx by 2.5% in the first quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after buying an additional 1,800 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Pulmonx in the third quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Pulmonx during the 2nd quarter valued at about $37,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after acquiring an additional 7,316 shares during the period. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.